ATE461706T1 - Verwendung eines antikörpers anti-pthrp(34-53) als antagonist von pthrp zur behandlung von nierenzellkarzinoma - Google Patents

Verwendung eines antikörpers anti-pthrp(34-53) als antagonist von pthrp zur behandlung von nierenzellkarzinoma

Info

Publication number
ATE461706T1
ATE461706T1 AT03748201T AT03748201T ATE461706T1 AT E461706 T1 ATE461706 T1 AT E461706T1 AT 03748201 T AT03748201 T AT 03748201T AT 03748201 T AT03748201 T AT 03748201T AT E461706 T1 ATE461706 T1 AT E461706T1
Authority
AT
Austria
Prior art keywords
pthrp
cell carcinoma
renal cell
antagonist
antibody
Prior art date
Application number
AT03748201T
Other languages
English (en)
Inventor
Thierry Massfelder
Herve Lang
Eric Schordan
Jean-Jacques Helwig
Original Assignee
Univ Strasbourg
Inst Nat Sante Rech Med
Hopitaux Universitaires De Str
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Strasbourg, Inst Nat Sante Rech Med, Hopitaux Universitaires De Str filed Critical Univ Strasbourg
Application granted granted Critical
Publication of ATE461706T1 publication Critical patent/ATE461706T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/26—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against hormones ; against hormone releasing or inhibiting factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/29—Parathyroid hormone, i.e. parathormone; Parathyroid hormone-related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Endocrinology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT03748201T 2002-07-05 2003-07-04 Verwendung eines antikörpers anti-pthrp(34-53) als antagonist von pthrp zur behandlung von nierenzellkarzinoma ATE461706T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0208501A FR2841788B1 (fr) 2002-07-05 2002-07-05 Utilisation d'antagonistes de la pthrp pour traiter le carcinome a cellules renales
PCT/FR2003/002084 WO2004004756A1 (fr) 2002-07-05 2003-07-04 UTILISATION D'ANTAGONISTES DE LA PTHrP POUR TRAITER LE CARCINOME A CELLULES RENALES

Publications (1)

Publication Number Publication Date
ATE461706T1 true ATE461706T1 (de) 2010-04-15

Family

ID=29725229

Family Applications (1)

Application Number Title Priority Date Filing Date
AT03748201T ATE461706T1 (de) 2002-07-05 2003-07-04 Verwendung eines antikörpers anti-pthrp(34-53) als antagonist von pthrp zur behandlung von nierenzellkarzinoma

Country Status (7)

Country Link
US (1) US7727526B2 (de)
EP (1) EP1521591B1 (de)
AT (1) ATE461706T1 (de)
AU (1) AU2003267511A1 (de)
DE (1) DE60331834D1 (de)
FR (1) FR2841788B1 (de)
WO (1) WO2004004756A1 (de)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8501929B2 (en) * 2007-08-17 2013-08-06 Biochrom Pharma Inc. PTHrP, its isoforms and antagonist thereto in the diagnosis and treatment of disease
US7897139B2 (en) * 2007-08-17 2011-03-01 Biochrom Pharma, Inc. PTHrP, its isoforms and antagonist thereto in the diagnosis and treatment of disease

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4231106B2 (ja) 1995-01-23 2009-02-25 ゼノテック インコーポレイティッド 骨溶解および転移を改善する方法
JP2000513201A (ja) 1995-07-20 2000-10-10 アイ・シー・エヌ・フアーマシユーテイカルズ 上皮小体ホルモン様たんぱく質に関連する化合物および方法
EP0962467A4 (de) 1996-09-26 2002-10-30 Chugai Pharmaceutical Co Ltd Antikörper gegen menschliches parathormon verwandten peptide
WO2001002011A1 (fr) * 1999-07-02 2001-01-11 Chugai Seiyaku Kabushiki Kaisha REMEDES CONTRE LES MALADIES CAUSEES PAR PTH OU PTHrP
US8029793B2 (en) 2000-04-28 2011-10-04 Chugai Seiyaku Kabushiki Kaisha Methods for inhibiting cell proliferation
IT1318517B1 (it) 2000-05-12 2003-08-27 Ist Naz Stud Cura Dei Tumori Polinucleotidi codificanti per forme polimorfiche della proteinapthrp, le proteine codificate, e loro applicazioni terapeutiche.

Also Published As

Publication number Publication date
DE60331834D1 (de) 2010-05-06
US7727526B2 (en) 2010-06-01
WO2004004756A8 (fr) 2004-06-10
FR2841788A1 (fr) 2004-01-09
EP1521591A1 (de) 2005-04-13
FR2841788B1 (fr) 2006-01-27
US20060003916A1 (en) 2006-01-05
AU2003267511A8 (en) 2004-01-23
WO2004004756A1 (fr) 2004-01-15
AU2003267511A1 (en) 2004-01-23
EP1521591B1 (de) 2010-03-24

Similar Documents

Publication Publication Date Title
IL258880A (en) Diarylhydantoin compounds
ATE453653T1 (de) Platinkomplexe zur behandlung von tumoren
ATE470439T1 (de) Verwendung von hif 1alfa modulatoren zur behandlung von krebs
SG170809A1 (en) Diarylthiohydantoin compounds
DE122009000069I1 (de) Verwendung von trifunktionellen bispezifischen und trispezifischen antikörpern zur behandlung von malignem aszites
NO20072355L (no) Cupredoxinderiverte transportmidler og metoder for fremstilling av disse
TW200612988A (en) Adjuvant therapy with the use of anti-glypican 3 antibody
ATE279208T1 (de) Verfahren und stoffe zur behandlung des prostatakarzinomes
DE602004016950D1 (de) Verwendung von cyclin-d1-hemmern zur brustkrebsbehandlung
ATE502025T1 (de) Arylcarboxamide und ihre verwendung als antitumormittel
PL374675A1 (en) Use of urease for inhibiting cancer cell growth
DE60328772D1 (de) Epothilonderivat zur behandlung von hepatoma und anderen krebserkrankungen
DE60331834D1 (de) VERWENDUNG EINES ANTIKÖRPERS ANTI-PTHrP(34-53) ALS ANTAGONIST VON PTHrP ZUR BEHANDLUNG VON NIERENZELLKARZINOMA
DE60123138D1 (de) Verwendung von progesteronrezeptorhemmern zur behandlung von steroid-resistentem brustkrebs
ATE541584T1 (de) Verfahren zur hemmung von krebsbildung und/oder metastasen bei einer person durch endogene c-met- liganden und -hemmer
JP2005513000A5 (de)
DE50311665D1 (de) Guanidinophenylalanin-verbindungen als urokinase-inhibitoren
ATE329597T1 (de) Die verwendung von einer 4- pyridylmethylphtalazine enthaltenden kombination zur behandlung von tumoren
ATE397003T1 (de) Ruthenium(ii)-komplexe zur behandlung von tumoren
MY151438A (en) Compositions and method for treatment of tumors
ATE411313T1 (de) Neue makrocyclen zur behandlung von krebserkrankungen
ATE432933T1 (de) Flavopereirinderivate zur krebstherapie
EA200600987A1 (ru) Применение сирамезина в лечении злокачественных опухолей

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties